Showing 1021-1030 of 5344 results for "".
- Upadacitinib Meets Primary Endpoint in Two Phase 3 Alopecia Areata Trialshttps://practicaldermatology.com/news/upadacitinib-meets-primary-endpoint-in-two-phase-3-alopecia-areata-trials/2488081/New data suggests upadacitinib was associated with significantly greater scalp hair regrowth than placebo among adults and adolescents with severe alopecia areata (AA), according to findings published online August 12 in JAMA Dermatology. The replicate UP-AA1 and UP-AA2 trials enr
- FDA Approves Tudriqev Plus Nivolumab for Advanced Melanomahttps://practicaldermatology.com/news/fda-approves-tudriqev-plus-nivolumab-for-advanced-melanoma/2488043/The FDA has granted accelerated approval to Tudriqev (vusolimogene oderparepvec-wtpg; Replimune, Inc.) in combination with nivolumab for adults with unresectable advanced cutaneous melanoma whose disease progressed on a programmed death receptor-1 (PD-1)–blocking antibody-based regimen, according
- ASDS Launches Financial, Technology Retreat for Dermatologistshttps://practicaldermatology.com/news/asds-launches-financial-technology-retreat-for-dermatologists/2488019/The American Society for Dermatologic Surgery (ASDS) is broadening its educational portfolio with the debut of $kin in the Game, a new financial and technology literacy retreat designed exclusively for dermatologists. The two-day program, developed in collaboration with Wilmington Trust,
- Early-Life Respiratory Infections Linked to Higher Risk of Childhood Atopic Dermatitishttps://practicaldermatology.com/news/early-life-respiratory-infections-linked-to-higher-risk-of-childhood-atopic-dermatitis/2488018/Children who experience a greater burden of respiratory infections during the first 3 years of life may face an increased risk of developing atopic dermatitis (AD), according to new research in JAMA Dermatology.
- Sanofi Halts Amlitelimab Development in Atopic Dermatitishttps://practicaldermatology.com/news/sanofi-halts-amlitelimab-development-in-atopic-dermatitis/2487921/Sanofi has announced it will discontinue the clinical development of amlitelimab for moderate-to-severe atopic dermatitis (AD), ending plans to submit the investigational therapy for global regulatory review after determining it would not provide a meaningful adva
- Farming-Associated Maternal Microbiome Linked With Lower Early Childhood Atopic Diseasehttps://practicaldermatology.com/news/study-farming-associated-maternal-microbiome-linked-with-lower-early-childhood-atopic-disease/2487882/A maternal gut microbiome shaped by a traditional farming lifestyle may help explain the protective effect of prenatal farm exposure against atopic disease in children, according to new research published in Allergy.
- Study: Anumigilimab Well Tolerated in HS and Palmoplantar Pustulosishttps://practicaldermatology.com/news/study-anumigilimab-well-tolerated-in-hs-and-palmoplantar-pustulosis/2487876/Anumigilimab was generally well tolerated in patients with hidradenitis suppurativa (HS) or palmoplantar pustulosis (PPP), while providing preliminary signals of clinical activity in both neutrophil-driven inflammatory skin diseases, results from a Phase 1b study
- Report: Dermatology M&A Momentum Sets Sights on Independent Practiceshttps://practicaldermatology.com/news/dermatology-ma-momentum-continues-as-buyers-chase-independent-practices/2487714/Private equity investment in dermatology continues at a rapid pace in 2026, with buyer demand remaining strong despite more than a decade of consolidation across the specialty, according to a new market update from Physician Growth Partners.
- Meta-analysis: Topical Ivermectin, Encapsulated BPO Show Strongest Efficacy in Rosaceahttps://practicaldermatology.com/news/topical-ivermectin-encapsulated-benzoyl-peroxide-show-strongest-efficacy-in-rosacea-network-meta-analysis/2487668/A systematic review and network meta-analysis of randomized clinical trials suggests that topical ivermectin and encapsulated benzoyl peroxide (E-BPO) provide greater efficacy than metronidazole for adults with moderate to severe rosacea.
- Letter Questions Strength of Evidence Linking Hair Relaxers to Uterine Cancerhttps://practicaldermatology.com/news/letter-questions-strength-of-evidence-linking-hair-relaxers-to-uterine-cancer/2487618/A recently published Letter to the Editor in the Journal of Drugs in Dermatology urged clinicians to interpret the growing body of research examining chemical hair relaxers and uterine cancer with caution, arguing that important methodological limitations prevent current evidence from es